文献速递临床试验与 GCP

补精益视片治疗眼压控制青光眼的多中心随机对照试验方案

Efficacy and safety of Bujing Yishi tablet for glaucoma with controlled IOP: study protocol for a multi-centre randomized controlled trial.
PubMed 文献 · Trials · 2020-05-25

本研究为6个月多中心前瞻性随机开放盲终点(PROBE)试验,拟纳入216例18-75岁眼压控制青光眼患者,按早中晚期分层后1:1随机接受补精益视片或甲钴胺片治疗,主要结局包括最佳矫正视力、视野、视觉诱发电位和HRT II,次要结局包括眼压和中医症状量表。

要点

  • 补精益视片是治疗眼压控制青光眼(GPCI)的院内标准制剂,但缺乏严格随机对照研究证据。
  • 试验采用PROBE设计,按青光眼早、中、晚期分层随机,对照药为甲钴胺片。
  • 主要结局涵盖视功能与视网膜结构指标,随访至24周,安全性评估至24周。

核心结论

  • 本研究旨在标准化、科学地评估补精益视片改善GPCI患者视功能的疗效与安全性。

研究设计与样本

  • 6个月多中心前瞻性随机开放盲终点(PROBE)试验,按早、中、晚期分层。
  • 计划纳入216例18-75岁眼压控制青光眼患者,1:1随机分入补精益视片组或甲钴胺片组。

关键数值与推荐

  • 主要结局包括最佳矫正视力(BCVA)、视野评估、视觉诱发电位(VEP)和Heidelberg视网膜断层扫描II(HRT II)。
  • 次要结局包括眼压(IOP)和中医临床症状量表。
  • 主要和次要结局在基线及第8、16、24周测量,安全性在基线及第12、24周评估。

临床怎么用

  • 若试验证实有效,补精益视片可作为GPCI患者改善视功能的新治疗策略。

局限性

  • 原文未报告研究结果,无法评价疗效与安全性。
  • 开放标签设计可能引入实施偏倚,但采用盲终点评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: As an irreversible, intractable disease with vision loss, glaucoma leads to permanent and progressive damage of visual function. Lowering high intraocular pressure (HIOP) is the first choice for treating glaucoma; however, the control of HIOP is not enough to prevent progressive vison loss. Currently, the therapies to treat glaucoma with controlled IOP (GPCI) are unsatisfactory. Chinese medicine is effective for improving visual function in patients with GPCI. Bujing Yishi tablets (BJYSP) have been the standard preparation for treating GPCI in our hospital for decades. However, no rigorous randomized controlled clinical studies have investigated its effects and safety. METHODS: This study will be a 6-month, multicenter, stratified trial following a prospective, randomized, open-label, blinded endpoint (PROBE) protocol. A total of 216 eligible GPCI patients aged 18-75 years will be stratified according to the early, moderate, and advanced stages of glaucoma. After stratifying, the participants will be randomly assigned to the BJYSP group or control group at a ratio of 1:1. Following randomization, participants in the BJYSP group and control group will receive BJYSP and mecobalamin tablets, respectively, for the same 6-month period. The primary outcomes will include the best-corrected visual acuity (BCVA), visual field assessment, visual evoked potential (VEP) test, and Heidelberg retina tomography II (HRT II); the secondary outcomes will include intraocular pressure (IOP) and Traditional Chinese medicine (TCM) clinical symptom scales. The primary and secondary outcomes will be measured at baseline and 8, 16, and 24 weeks thereafter. Safety assessments will also be evaluated at baseline and 12 and 24 weeks thereafter. DISCUSSION: This study will be a standardized, scientific, clinical trial designed to evaluate the therapeutic effects and safety of BJYSP as a novel therapeutic strategy for improving visual function in patients with GPCI. TRIAL REGISTRATION: Chinese Clinical Trial Registry, ChiCTR1800016431. Registered on 1 June 2018.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Liu H, Li X, Zhang Z, et al. Efficacy and safety of Bujing Yishi tablet for glaucoma with controlled IOP: study protocol for a multi-centre randomized controlled trial. Trials. 2020. PMID: 32450908. doi:10.1186/s13063-020-04249-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。